drugset / Trial / NCT02759640
A Phase I Trial of HS-10241 in Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This is a phase 1, open-label, dose-escalation trial of HS-10241 as monotherapy in subjects with solid tumors. HS-10241 will be administered orally once daily.
Timeline
- Start
- 2016-09
- Primary completion
- 2018-03
- Completion
- 2018-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HS-10241 | Small molecule | 100 mg | Oral |
| Subject | HS-10241 | Small molecule | 200 mg | Oral |
| Subject | HS-10241 | Small molecule | 340 mg | Oral |
| Subject | HS-10241 | Small molecule | 500 mg | Oral |
| Subject | HS-10241 | Small molecule | 700 mg | Oral |